Finding and targeting drug-resistant cells in small cell lung cancer
Detection and elimination of drug tolerant persister cells in small cell lung cancer
This study is looking at small cell lung cancer to find ways to target stubborn cells that make the cancer hard to treat, with the hope of developing better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11102388 on NIH RePORTER |
What this research studies
This research focuses on small cell lung cancer (SCLC), a type of cancer known for its aggressive nature and tendency to recur after initial treatment. The project aims to identify and eliminate drug-tolerant persister cells (DTPCs) that contribute to the cancer's resistance to therapy. By utilizing a collection of patient samples and advanced models, the research team will explore the mechanisms behind the cancer's response to treatment and its subsequent resistance. Patients may benefit from new strategies that specifically target these resistant cells, potentially leading to more effective treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with small cell lung cancer who are undergoing or have undergone treatment.
Not a fit: Patients with other types of lung cancer or those who are not currently receiving treatment for small cell lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for small cell lung cancer patients by effectively targeting drug-resistant cancer cells.
How similar studies have performed: Previous research has shown promise in targeting drug-resistant cancer cells, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Gay, Carl Michael — University of Tx Md Anderson Can Ctr
- Study coordinator: Gay, Carl Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.